OREM, Utah, Feb. 19, 2026 /PRNewswire/ — Dymicron®, a privately held medical device company advancing next-generation spinal motion-preservation technology, today announced the appointment of Peter Wehrly, one of the spinal industry’s most seasoned C-suite executives, to its Board of Directors. Mr. Wehrly brings more than forty years of leadership experience, including roles as CEO, President, Chairman, and global...

Dymicron®, a privately held medical device company pioneering advanced spinal technologies, today announced the successful enrollment and treatment of the first patient in its Triadyme®-C Investigational Device Exemption (IDE) clinical trial. This milestone marks the initiation of a U.S. clinical study evaluating the safety and effectiveness of the Triadyme-C cervical artificial disc.